Raymond James Financial Lowers Insulet (NASDAQ:PODD) Price Target to $355.00

Insulet (NASDAQ:PODD) had its target price dropped by investment analysts at Raymond James Financial from $385.00 to $355.00 in a research report issued to clients and investors on Thursday,MarketScreener reports. The brokerage presently has an “outperform” rating on the medical instruments supplier’s stock. Raymond James Financial’s price target points to a potential upside of 48.36% from the company’s current price.

Several other research analysts have also commented on PODD. Oppenheimer dropped their price objective on shares of Insulet from $365.00 to $300.00 and set an “outperform” rating for the company in a research note on Thursday. Evercore set a $340.00 price objective on shares of Insulet in a research report on Thursday. Sanford C. Bernstein decreased their target price on Insulet from $380.00 to $330.00 and set an “outperform” rating for the company in a report on Thursday. Citigroup cut their price objective on shares of Insulet from $380.00 to $345.00 and set a “buy” rating for the company in a report on Thursday. Finally, Royal Bank Of Canada upped their price objective on shares of Insulet from $370.00 to $380.00 and gave the stock an “outperform” rating in a research report on Friday, November 21st. Twenty investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $354.57.

Insulet Price Performance

Insulet stock traded down $9.82 during mid-day trading on Thursday, reaching $239.29. 83,522 shares of the company’s stock traded hands, compared to its average volume of 976,786. Insulet has a 12-month low of $230.05 and a 12-month high of $354.88. The company has a market cap of $16.83 billion, a price-to-earnings ratio of 68.44, a PEG ratio of 1.46 and a beta of 1.41. The stock has a 50 day moving average of $273.52 and a two-hundred day moving average of $305.11. The company has a quick ratio of 2.18, a current ratio of 2.81 and a debt-to-equity ratio of 0.61.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.48 by $0.07. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The firm had revenue of $783.80 million for the quarter, compared to analysts’ expectations of $768.31 million. During the same period in the prior year, the company earned $1.15 EPS. The business’s revenue was up 31.2% compared to the same quarter last year. Equities analysts forecast that Insulet will post 3.92 earnings per share for the current year.

Institutional Trading of Insulet

A number of institutional investors and hedge funds have recently modified their holdings of PODD. Mcguire Capital Advisors Inc. purchased a new stake in shares of Insulet in the 4th quarter valued at approximately $29,000. T. Rowe Price Investment Management Inc. boosted its position in shares of Insulet by 275.6% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 338 shares of the medical instruments supplier’s stock worth $97,000 after acquiring an additional 248 shares in the last quarter. Claris Financial LLC acquired a new stake in Insulet during the 4th quarter worth $568,000. Invesco Ltd. lifted its stake in Insulet by 10.5% in the fourth quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock valued at $420,835,000 after buying an additional 141,167 shares during the last quarter. Finally, Corient Private Wealth LLC lifted its holdings in shares of Insulet by 938.1% during the fourth quarter. Corient Private Wealth LLC now owns 112,245 shares of the medical instruments supplier’s stock worth $31,905,000 after purchasing an additional 101,432 shares during the period.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Company beat Q4 EPS and revenue estimates, delivered ~31% revenue growth year‑over‑year, reported margin expansion and gave an upbeat 2026 outlook — this explains the initial surge in the stock after results. Insulet (PODD) Tops Q4 Earnings and Revenue Estimates
• Positive Sentiment: Insulet expanded its share repurchase program alongside the strong Q4 print — buybacks are typically supportive to equity value and were highlighted by management. Insulet Posts Strong Q4 Results, Expands Share Repurchase Program
• Positive Sentiment: Multiple brokers reaffirmed buy/overweight stances (BTIG reiterated Buy with a $380 PT; other firms maintained constructive views), supporting medium‑term investor confidence. BTIG Research Reiterates “Buy” Rating for Insulet (NASDAQ:PODD)
• Neutral Sentiment: Coverage remains broadly bullish overall (several analysts kept buy/outperform ratings), but some firms updated their models after the print — expect divergent price targets and advice in the near term. What Are Wall Street Analysts’ Target Price for Insulet Stock?
• Neutral Sentiment: Short‑interest reporting in the feed is noisy/garbled (shows 0 shares and 0 days‑to‑cover) — no clear signal from short activity based on the provided data. (No external link available.)
• Negative Sentiment: Several major brokers trimmed price targets after the results (Citigroup cut to $345, JPMorgan to $340, Leerink to $360) — even with maintained buy/overweight ratings, lower targets create pressure on near‑term upside expectations and may have contributed to profit‑taking. Benzinga coverage of analyst price target changes

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.